No significant reduction in cognitive or functional decline was observed with simufilam compared with placebo. A phase 3 trial evaluating simufilam for the treatment of Alzheimer disease (AD) did not ...

Findings showed no significant reduction in cognitive or functional decline with simufilam when compared with placebo. Topline results were announced from a phase 3 trial evaluating simufilam, an oral ...

Please provide your email address to receive an email when new articles are posted on . Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed ...

Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, ...

Cassava Sciences' presentation at the CTAD Conference undermines its claim that simufilam is an effective treatment for Alzheimer's Disease. The drug appears to have little to no effect on moderate ...

Cassava Sciences Inc SAVA announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus placebo ...

Oral Simufilam Continues to be Safe, Well Tolerated. AUSTIN, Texas, July 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced top-line clinical ...